Kamada announces FDA acceptance of Inhaled AAT program path forward

Press Release / Apr. 16, 2019

Kamada announced today receipt of a letter from the U.S. Food and Drug Administration (FDA or the Agency) stating that the Company has satisfactorily addressed the concerns and questions regarding its Inhaled Alpha-1-Antitrypsin (Inhaled AAT) program for the treatment of Alpha-1 Antitrypsin Deficiency (AATD), previously communicated by the Agency.

Kamada Awarded the Israeli Outstanding Exporter Award for 2017

Press Release / Mar. 14, 2019

Kamada announced today that it has been awarded the Israeli Outstanding Exporter Award for 2017 by the Foreign Trade Department of the Israeli Ministry of Economy and Industry. The Company received the award for the continued growth demonstrated in its export revenues.

Kamada Files Annual Report for the Year Ended December 31, 2018

Press Release / Feb. 27, 2019

Kamada today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2018 with the U.S. Securities and Exchange Commission (the “SEC”).

Kamada Reports Financial Results for Fourth Quarter and Fiscal Year 2018

Press Release / Feb. 12, 2019

Kamada announced today financial results for the three and 12-months
ended December 31, 2018.

Kamada Announces Additional Interim Results from Phase 2 Proof of Concept Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection

Press Release / Feb. 7, 2019

Kamada’s IV-AAT demonstrated a trend towards improvements in multiple clinical outcomes, including days on mechanical ventilation post-transplant, pulmonary function at week 4 and week 48 post-transplant and six-minute walk test.
Top-line Results Anticipated in H2 2019

Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2018 Financial Results and Host Conference Call on February 12

Press Release / Feb. 5, 2019

Kamada management will host an investment community conference call on Tuesday, February 12 at 8:30am Eastern Time to discuss these results and answer questions. 

Kamada Appoints Senior Biopharmaceutical Executive Michal Ayalon, Ph.D., as Vice President of Research and Development

Press Release / Jan. 30, 2019

announced today the appointment of Michal Ayalon, Ph.D., as Vice President of Research and Development.  She will oversee all of Kamada's R&D and IP activities, and report directly to Amir London, Kamada’s Chief Executive Officer.

Dr. Ayalon will succeed Liliana Bar, Ph.D. who has served as Kamada’s VP R&D since 2012 and is retiring next month.  

Kamada Announces Preliminary Revenue for Fourth Quarter and Full-Year 2018

Press Release / Jan. 2, 2019

Kamada announced today preliminary and unaudited total revenues for the fourth quarter and full-year 2018. Total revenue for the fourth quarter of 2018 is expected to be between $46.7 million and $48.7 million. Total revenue for full-year 2018 is expected to be between $113 million and $115 million.

Kamada announced the extension of an ongoing investigator initiated, proof-of-concept study evaluating the potential benefit of the Company’s liquid Alpha-1 Antitrypsin (AAT) on liver preservation and transplant rejection prevention.

Press Release / Sep. 5, 2018

Kamada Announces Extension of Collaboration with Massachusetts General Hospital for a Proof-of-Concept Study Evaluating the Potential Benefit of Liquid Alpha-1 Antitrypsin on Liver Preservation Prior to Transplantation.

Kamada Provides Updated Full-Year 2018 Revenue Guidance

Press Release / Aug. 29, 2018

As result of the recent labor strike part of 2018 shipments are likely to be delayed to early 2019 Subsequent update and full-year 2019 revenue guidance to be provided later this year.

out of 25 items.